SUBSCRIBE
SUBSCRIBE

GLP-1

Business
Secretive Moderna Inks mRNA Heart Failure Deal With AstraZeneca
The companies will advance the new Relaxin development candidate, AZD7970, toward the clinic as an investigational treatment for heart failure.
November 1, 2017
 · 
4 min read
Biotech Beach
Organovo Presents New Preclinical Data on 3D Bioprinted Human Liver Tissues for the Treatment of Inborn Errors of Metabolism at The Liver Meeting 2017 (AASLD)
This data will be presented by Vaidehi Joshi, Scientist I, Therapeutics, at Organovo.
October 20, 2017
 · 
7 min read
A Novo Nordisk flag flies in the wind/Courtesy jor
FDA
Eli Lilly Looks Over Its Shoulder After Novo Nordisk Wins FDA Panel Backing for Diabetes Drug
An advisory panel with the FDA gave a near unanimous support to Novo Nordisk’s diabetes drug semaglutide, a long-acting GLP-1 analogue.
October 19, 2017
 · 
2 min read
 · 
Alex Keown
Ablynx Seals Nanobody R&D Deal Worth $2.8 Billion With Drug Giant Sanofi
Business
Sanofi R&D Boss Thinks His Team is Ready to Survive Without Besties Regeneron and Alnylam
September 21, 2017
 · 
2 min read
Harmony Biosciences Gains U.S. Rights to Pitolisant, Raises $270 Million
Business
Biotech Gene Therapy Startup Apic Bio Launches in Cambridge, Massachusetts
August 22, 2017
 · 
2 min read
Novo Nordisk A/S’s Diabetes Drug Beats Out Eli Lilly’s Trulicity in Phase III Trials
Drug Development
Novo Nordisk A/S’s Diabetes Drug Beats Out Eli Lilly’s Trulicity in Phase III Trials
August 17, 2017
 · 
2 min read
Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks
Drug Development
Galapagos’ Phase II Results With GLPG1690 are ‘Extremely Exciting’
August 10, 2017
 · 
2 min read
Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives
Business
Dimension Therapeutics Pink Slips 25% of Workforce
June 27, 2017
 · 
2 min read
Biotech Vets Launch Arrakis With $38 Million and Will be Helmed By Biogen Alum Michael Gilman
Business
Fast-Growing Intarcia Awaits Crucial FDA Decision in New Boston HQ
May 8, 2017
 · 
3 min read
3 Biotechs That Could be Taken Out This Quarter
Deals
PE Firm in Talks to Buy VWR in Deal Worth $5 Billion
May 4, 2017
 · 
2 min read
Load More
PRESS RELEASES
Press Releases
Eccogene Announces Positive Topline Results from Phase 1b Trial of Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, in Adult Participants Living with Obesity/Overweight, with or without Type 2 Diabetes in China
February 11, 2026
 · 
4 min read
Press Releases
Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide
February 10, 2026
 · 
8 min read
Press Releases
Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial
February 4, 2026
 · 
9 min read
Press Releases
Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
February 3, 2026
 · 
6 min read
Press Releases
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility
February 1, 2026
 · 
8 min read
Press Releases
LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
January 30, 2026
 · 
5 min read
Press Releases
BetterWay Launches GLP-1 Blood Testing Panel at Retail Locations in Austin and Temple
January 30, 2026
 · 
2 min read
Press Releases
Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation
January 29, 2026
 · 
8 min read
Press Releases
Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users
January 28, 2026
 · 
3 min read
Press Releases
Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More
January 28, 2026
 · 
3 min read
Press Releases
Baseline Therapeutics Launches to Advance GLP-1RA Phase 3 Program in Alcohol Use Disorder
January 28, 2026
 · 
3 min read
Press Releases
Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity
January 27, 2026
 · 
4 min read
Press Releases
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity
January 27, 2026
 · 
6 min read
Press Releases
Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes
January 26, 2026
 · 
4 min read
Press Releases
CORXEL Announces $287 million Series D1 Financing to Further Advance Its Cardiometabolic Pipeline including Oral Small Molecule GLP-1 Receptor Agonist
January 23, 2026
 · 
3 min read
Press Releases
Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
January 20, 2026
 · 
4 min read
Press Releases
RO ANNOUNCES RESEARCH COLLABORATION TO BETTER UNDERSTAND AND IMPROVE THE REAL-WORLD PATIENT EXPERIENCE WITH GLP-1S
January 13, 2026
 · 
2 min read
Press Releases
Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531)
January 13, 2026
 · 
6 min read
Press Releases
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones
January 12, 2026
 · 
8 min read
Press Releases
LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform
January 9, 2026
 · 
6 min read
Load More